“Infectobesity: viral infections (especially with human adenovirus-36: Ad-36) may be a cause of obesity

2009 ◽  
Vol 72 (4) ◽  
pp. 383-388 ◽  
Author(s):  
Vincent van Ginneken ◽  
Laura Sitnyakowsky ◽  
Jonathan E. Jeffery
2018 ◽  
Vol 38 (4) ◽  
Author(s):  
Yan Zhou ◽  
Qi Pan ◽  
Xiaoxia Wang ◽  
Lina Zhang ◽  
Fei Xiao ◽  
...  

The study aimed to explore the prevalence of human adenovirus-36 (HAdV-36) infection and the association of HAdV-36 with obesity in Chinese Han population. A qualitative determination using ELISA was performed to determine by duplication of the antibodies to HAdV-36 in the serum samples. Logistic regression analysis was used to analyze the association between HAdV-36 seropositivity and obesity. The overall HAdV-36 seroprevalence was 49.8% amongst 824 participants. The prevalence of HAdV-36 seropositive was 42.9 and 51.4% in the obese and non-obese participants, respectively, which was not statistically significant (P=0.05). There were significant differences in the anthropometric and biochemical parameters observed between the two groups except for height (P=0.067) and total cholesterol (TC) (P<0.29). After the adjustment for age and gender, HAdV-36 seropositivity was a protective factor for obesity (odds ratio (OR) = 0.69, 95% confidence intervals (95% CI) = 0.48–0.97, P=0.03). In the male population, the adjusted OR for AD-36 antibody-positive status was statistically decreased for obese adults (OR = 0.59; 95% CI = 0.39–0.91; P=0.02). However, the similar result was not obtained in the female population (OR = 0.90; 95% CI = 0.48–1.67; P=0.73). We found a high prevalence of HAdV-36 infection in China and significant association between HAdV-36 infection and obesity or weight gain after the adjustment for age and gender. The HAdV-36 infection may be related to the weight loss in Chinese Han population, especially in the male group, which needs to be further confirmed.


2009 ◽  
Vol 34 (1) ◽  
pp. 89-93 ◽  
Author(s):  
H-N Na ◽  
Y-M Hong ◽  
J Kim ◽  
H-K Kim ◽  
I Jo ◽  
...  

2004 ◽  
Vol 29 (3) ◽  
pp. 281-286 ◽  
Author(s):  
R L Atkinson ◽  
N V Dhurandhar ◽  
D B Allison ◽  
R L Bowen ◽  
B A Israel ◽  
...  

1980 ◽  
Vol 64 (3) ◽  
pp. 225-233 ◽  
Author(s):  
R. Wigand ◽  
H. Gelderblom ◽  
G. Wadell

2019 ◽  
Author(s):  
Bahareh Nikooyeh ◽  
Bruce Hollis ◽  
Tirang Reza Neyestani

Abstract Background. Among the causative factors of obesity, a rather newly proposed theory is viral infections. The association of ADV-36 infection and obesity has been reported by some research groups in children. We hypothesized that the association between ADV-36 infection and adiposity may be mediated by sub-optimal vitamin D status of the host. To examine this hypothesis, we conducted a case control study on children and adolescents with normal weight, over weight and obesity. Methods. In total, 91 (normal weight: 33, overweight: 33, obese: 25) apparently healthy children aged 5-18 years were randomly selected from the registered population at National Food and Nutrition Surveillance Program (NFNS). The groups were matched based on age and sex. Anthropometric, biochemical and serological assessments were performed. Results. The amount of anti-ADV36-Ab increased whereas circulating concentrations of calcidiol decreased across BMI categories with higher amounts in normal weight than in overweight and obese children (31.0±16.4, 22.5±10.5 and 21.9±9.8 nmol/L, respectively, p=0.004). Logistic regression analysis revealed that for each unit increment of anti-ADV36-Ab, the chance of increase in weight was 8.5 times (OR: 8.5, p=0.029). Interestingly, when 25(OH)D was introduced into the model, anti-ADV36-Ab was no longer the predictor of weight increment and the chance of increase in weight reduced 5% for each unit increase in calcidiol concentration (OR: 0.95, p=0.012). Conclusion. It is suggested that ADV36-induced lipogenesis and weight gain may be mediated by vitamin D deficiency in obese children. Further studies are warranted.


2020 ◽  
Vol 8 (9) ◽  
pp. 1284 ◽  
Author(s):  
Bratati Saha ◽  
Robin J. Parks

Human adenovirus (HAdV) is a very common pathogen that typically causes minor disease in most patients. However, the virus can cause significant morbidity and mortality in certain populations, including young children, the elderly, and those with compromised immune systems. Currently, there are no approved therapeutics to treat HAdV infections, and the standard treatment relies on drugs approved to combat other viral infections. Such treatments often show inconsistent efficacy, and therefore, more effective antiviral therapies are necessary. In this review, we discuss recent developments in the search for new chemical and biological anti-HAdV therapeutics, including drugs that are currently undergoing preclinical/clinical testing, and small molecule screens for the identification of novel compounds that abrogate HAdV replication and disease.


Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1285
Author(s):  
Giovanni Tarantino ◽  
Vincenzo Citro ◽  
Mauro Cataldi

Infection has recently started receiving greater attention as an unusual causative/inducing factor of obesity. Indeed, the biological plausibility of infectobesity includes direct roles of some viruses to reprogram host metabolism toward a more lipogenic and adipogenic status. Furthermore, the probability that humans may exchange microbiota components (virome/virobiota) points out that the altered response of IFN and other cytokines, which surfaces as a central mechanism for adipogenesis and obesity-associated immune suppression, is due to the fact that gut microbiota uphold intrinsic IFN signaling. Last but not least, the adaptation of both host immune and metabolic system under persistent viral infections play a central role in these phenomena. We hereby discuss the possible link between adenovirus and obesity-related nonalcoholic fatty liver disease (NAFLD). The mechanisms of adenovirus-36 (Ad-36) involvement in hepatic steatosis/NAFLD consist in reducing leptin gene expression and insulin sensitivity, augmenting glucose uptake, activating the lipogenic and pro-inflammatory pathways in adipose tissue, and increasing the level of macrophage chemoattractant protein-1, all of these ultimately leading to chronic inflammation and altered lipid metabolism. Moreover, by reducing leptin expression and secretion Ad-36 may have in turn an obesogenic effect through increased food intake or decreased energy expenditure via altered fat metabolism. Finally, Ad-36 is involved in upregulation of cAMP, phosphatidylinositol 3-kinase, and p38 signaling pathways, downregulation of Wnt10b expression, increased expression of CCAAT/enhancer binding protein-beta, and peroxisome proliferator-activated receptor gamma 2 with consequential lipid accumulation.


2018 ◽  
Vol 3 (1) ◽  
pp. 210-216
Author(s):  
Mehrevan M. Abdel-moniem ◽  
Ola M. Ibrahim ◽  
Azza A. Gabr ◽  
EL-Sonousy WM ◽  
Manal A. Mohsen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document